Preclinical
XtalPi HIV entry candidate
XtalPi with Viva-Thera: company profile
Preclinical candidate per company
Since , the date of the source that reports this phase.
Summary
XtalPi HIV entry candidate is a program from XtalPi with Viva-Thera. The source describes it as small molecule. It is being developed for HIV. Per the company, it was at Preclinical candidate as of Sep 22, 2026. The AI role named in the source is molecule design. The latest dated source is from Sep 22, 2026.
Built only from the sources listed on this page.
Facts
- Company
- XtalPi with Viva-Thera
- Indication
- HIV
- Therapeutic area
- Infectious disease
- Modality
- Small molecule
- AI role
- Molecule design
- Phase in the source
- Preclinical candidate, as of Sep 22, 2026
- Phase source
- X only
- Board column
- Preclinical
- Trial record
- none (preclinical)
AI evidence
AI source: Company
“The partners completed discovery and optimization in seven months by combining Viva-Thera's atomic-resolution structural research with XtalPi's AI drug design and automation platform.”
Milestone timeline
-
Official X post: Preclinical candidate
Spot an error? Tell me and I'll fix it.